Regencell Bioscience Holdings stock
RGCNASDAQRegencell Bioscience Holdings Limited, HealthcareISIN KYG7487R1002
31Score 31 out of 100, Weak
Price and trend
24 / 100
Price history
−63% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 68% below it.
Since July 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Sharply down: the price has fallen very quickly lately (RSI 25).
The price is 90% below its 52-week high. Largest decline in 5 years: 94% (June 2025 to July 2026).
Chart figures for advanced users
- SMA 50$6.82
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$16.10
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)25
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.78
- The lowest closing price of the last twelve months.
- Resistance$52.88
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Regencell Bioscience Holdings Limited belongs to the Drug Manufacturers (Specialty & Generic) industry (Hong Kong SAR China) and, with a market value of $2.54B, is number 47 of 78 companies in its industry on MEQIRI.
- MEQIRI Score 31 out of 100 (Weak): rank 685 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $14.19M, financial debt $295.81K.Stability 69
Weaknesses
- Volatile share priceVolatility 148% a year over the last 12 months.Stability 69
- Loss-makingLoss of $11.7M over the last 12 months.Fundamentals 17
- Share price fell sharplyDown 65% over the last 12 months.Momentum 12
The score is held back by profitability and momentum.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 0%, operating 0%, net 0%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- No date announced.
- Last reported
- 28 Oct 2026EPS reported −$0.01
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Regencell Bioscience Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 31
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Shenzhen Salubris Pharmaceuticals002294.SZ $5.03B53
- Laboratorios Farmaceuticos RoviROVI.MC $4.02B82
- Siegfried HoldingSFZN.SW $3.77B55
- Bausch Health CompaniesBHC $3.13B61
- HUTCHMED (China)HCM $2.63B45
- AlmirallALM.MC $2.61B45
- PerrigoPRGO $2.3B48
- Trulieve CannabisTRLV $2.17B48
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Jun 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2022)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.